These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14511021)

  • 41. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversible hair depigmentation in a patient treated with imatinib.
    Mariani S; Abruzzese E; Basciani S; Fiore D; Persichetti A; Watanabe M; Spera G; Gnessi L
    Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
    [No Abstract]   [Full Text] [Related]  

  • 43. Interstitial pneumonitis during imatinib therapy.
    Isshiki I; Yamaguchi K; Okamoto S
    Br J Haematol; 2004 May; 125(4):420. PubMed ID: 15142112
    [No Abstract]   [Full Text] [Related]  

  • 44. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
    Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
    Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
    Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
    Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
    [No Abstract]   [Full Text] [Related]  

  • 46. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
    Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
    Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
    Dora JM; Leie MA; Netto B; Fogliatto LM; Silla L; Torres F; Maia AL
    Eur J Endocrinol; 2008 May; 158(5):771-2. PubMed ID: 18426838
    [No Abstract]   [Full Text] [Related]  

  • 49. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
    Lokeshwar N; Kumar L; Kumari M
    Leuk Lymphoma; 2005 May; 46(5):781-4. PubMed ID: 16019519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 51. Pityriasis rosea associated with imatinib (STI571, Gleevec).
    Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
    Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse events after imatinib mesylate therapy.
    Elliott MA; Mesa RA; Tefferi A
    N Engl J Med; 2002 Feb; 346(9):712-3. PubMed ID: 11870257
    [No Abstract]   [Full Text] [Related]  

  • 55. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
    Kawakami T; Kawanabe T; Soma Y
    Acta Derm Venereol; 2009; 89(3):325-6. PubMed ID: 19479144
    [No Abstract]   [Full Text] [Related]  

  • 56. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
    Gafter-Gvili A; Leader A; Gurion R; Vidal L; Ram R; Shacham-Abulafia A; Ben-Bassat I; Lishner M; Shpilberg O; Raanani P
    Am J Hematol; 2011 Aug; 86(8):657-62. PubMed ID: 21761431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chlordiazepoxide for imatinib-induced muscular cramps.
    Medeiros BC; Lipton JH
    Eur J Haematol; 2006 Dec; 77(6):538. PubMed ID: 17105448
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
    Park MA; Volcheck GW; Guarderas JC
    Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 60. Imatinib mesylate (gleevec) hepatotoxicity.
    Mindikoglu AL; Regev A; Bejarano PA; Martinez EJ; Jeffers LJ; Schiff ER
    Dig Dis Sci; 2007 Feb; 52(2):598-601. PubMed ID: 17219077
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.